4.7 Article

Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 10, Issue 12, Pages 1315-+

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2012.07.006

Keywords

Ulcerative Colitis; Colectomy; Inflammatory Bowel Disease; Inpatient Management

Funding

  1. Abbott
  2. ActoGenIX NV
  3. AGI Therapeutics, Inc
  4. Alba Therapeutics Corp
  5. Albireo
  6. Alfa Wasserman
  7. Amgen
  8. AM-Pharma BV
  9. Anaphore
  10. Astellas
  11. Athersys, Inc
  12. Atlantic Healthcare, Ltd
  13. Aptalis
  14. BioBalance Corp
  15. Boehringer-Ingelheim
  16. Bristol-Myers Squibb
  17. Celgene
  18. Celek Pharmaceuticals
  19. Cellerix SL
  20. Cerimon Pharmaceuticals
  21. ChemoCentryx
  22. CoMentis
  23. Cosmo Technologies
  24. Coronado Biosciences
  25. Cytokine Pharmasciences
  26. Eagle Pharmaceuticals
  27. EnGene, Inc
  28. Eli Lilly
  29. Enteromedics
  30. Exagen Diagnostics, Inc
  31. Ferring Pharmaceuticals
  32. Flexio Therapeutics, Inc
  33. Funxional Therapeutics, Ltd
  34. Genzyme, Corp
  35. Gilead Sciences
  36. Given Imaging
  37. GSK
  38. Human Genome Sciences
  39. Ironwood Pharmaceuticals
  40. KaloBios Pharmaceuticals
  41. Lexicon Pharmaceuticals
  42. Lycera Corp
  43. Meda Pharmaceuticals
  44. Merck Research Laboratories
  45. Merck Serono
  46. Millennium Pharmaceuticals
  47. Nisshin Kyorin Pharmaceuticals
  48. Novo Nordisk
  49. NPS Pharmaceuticals
  50. Optimer Pharmaceuticals
  51. Orexigen Therapeutics, Inc
  52. PDL Biopharma
  53. Pfizer
  54. Procter and Gamble
  55. Prometheus Laboratories
  56. ProtAb, Ltd
  57. Purgenesis Technologies, Inc
  58. Relypsa, Inc
  59. Roche
  60. Salient Pharmaceuticals
  61. Salix Pharmaceuticals
  62. Santarus
  63. Schering Plough
  64. Shire Pharmaceuticals
  65. Sigmoid Pharma, Ltd
  66. Sirtris Pharmaceuticals
  67. SLA Pharma UK, Ltd
  68. Targacept
  69. Teva Pharmaceuticals
  70. Therakos
  71. Tilliotts Pharma AG
  72. TxCell SA
  73. UCB Pharma
  74. Viamet Pharmaceuticals
  75. Vascular Biogenics, Ltd
  76. Warner Chilcott UK, Ltd
  77. Wyeth
  78. Genentech
  79. Janssen
  80. Novartis

Ask authors/readers for more resources

Ulcerative colitis is a chronic inflammatory disease of the colon; as many as 25% of patients with this disease require hospitalization. The goals of hospitalization are to assess disease severity, exclude infection, administer rapidly acting and highly effective medication regimens, and determine response. During hospitalization, patients should be given venous thromboembolism prophylaxis and monitored for the development of toxic megacolon. Patients who do not respond to intravenous corticosteroids should be considered for rescue therapy with infliximab or cyclosporine. Patients who are refractory to medical therapies or who develop toxic megacolon should be evaluated promptly for colectomy. Patients who do respond to medical therapies should be discharged on an appropriate maintenance regimen when they meet discharge criteria. We review practical evidence-based management principles and propose a day-by-day algorithm for managing patients hospitalized for ulcerative colitis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available